Immunogenic compositions for use in pneumococcal vaccines

Abstract

An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 15, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said immunogenic compositions.

1 . A set of immunogenic compositions comprising: (a) a first immunogenic composition comprising a glycoconjugate from  S. pneumoniae  serotype 15B; and (b) a second immunogenic composition comprising a glycoconjugate from  S. pneumoniae  serotype 15A and a glycoconjugate from  S. pneumoniae  serotype 15C, wherein said compositions are for concurrent, concomitant or sequential administration. 
     
     
         2 . A set of immunogenic compositions comprising: (a) a first immunogenic composition comprising a glycoconjugate from  S. pneumoniae  serotype 15B; and (b) a second immunogenic composition comprising a glycoconjugate from  S. pneumoniae  serotype 15A, wherein said compositions do not comprise capsular saccharide from  S. pneumoniae  serotypes 15C and wherein said compositions are for concurrent, concomitant or sequential administration. 
     
     
         3 . The set of immunogenic compositions of  claim 1 , wherein said first immunogenic composition further comprises, in addition to a glycoconjugate from  S. pneumoniae  serotype 15B, glycoconjugates from  S. pneumoniae  serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 18C, 19A, 19F, 22F, 23F and 33F. 
     
     
         4 . The set of immunogenic compositions of  claim 1 , wherein the glycoconjugates of the first immunogenic compositions are all individually conjugated to CRM 197 . 
     
     
         5 . The set of immunogenic compositions of  claim 1 , wherein the first immunogenic composition comprises from 7 to 25 different serotypes of  S. pneumoniae.    
     
     
         6 . The set of immunogenic compositions of  claim 1 , wherein, the first immunogenic composition is a 20-valent pneumococcal conjugate composition wherein in addition to a glycoconjugate from  S. pneumoniae  serotype 15B, said composition further comprises, glycoconjugates from  S. pneumoniae  serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 18C, 19A, 19F, 23F, 22F and 33F individually conjugated to CRM 197 . 
     
     
         7 . The set of immunogenic compositions of  claim 1 , wherein the second immunogenic composition comprises from 7 to 25 different serotypes of  S. pneumoniae.    
     
     
         8 . An immunogenic composition comprising a glycoconjugate from  S. pneumoniae  serotype 15A wherein said immunogenic composition does not comprise glycoconjugates from  S. pneumoniae  serotypes 4, 6B, 9V, 14, 15B, 15C, 18C, 19F and 23F, for use in a method of complementing a pneumococcal conjugate vaccine which comprises a glycoconjugate from  S. pneumoniae  serotype 15B but which does not comprise glycoconjugates from  S. pneumoniae  serotypes 15A. 
     
     
         9 . The immunogenic composition for use of  claim 8  wherein said immunogenic composition does not comprise glycoconjugates from  S. pneumoniae  serotypes 1, 4, 5, 6B, 7F, 9V, 14, 15B, 15C, 18C, 19F and 23F. 
     
     
         10 . The immunogenic composition for use of  claim 8 , comprising glycoconjugates from 2 to 25 different serotypes of  S. pneumoniae.    
     
     
         11 . The immunogenic composition for use of  claim 8 , which is a 2 to 24-valent pneumococcal conjugate composition. 
     
     
         12 . A kit comprising the set of immunogenic compositions of  claim 1 , and an information leaflet.